Investor Hub Answers

Most certainly. The intent is to absolutely get the product into as many different indications and markets as possible. For other Bitoech/Pharma companies looking at getting into CBD for a specific indication, the pitch is essentially that they should start with our product and get a three year head start. They can either, a) start from scratch themselves, or b) license a novel formulation with increased bioavailability, patent protection, GMP manufacturing with all associated validation, 2 year stability, and human Phase I PK data. That's an early phase data pack. From there, you can leap straight into Phase II studies for a whole range of new indications. That's what got Medterra/Perland over the line for arthritis. We're in discussions with a few others now regarding further indications.

The CBD capsule will be in up to four separate clinical trials (with different indications) this year. Sleep (paid for by us), osteoarthritis (Perland), and two further clinical trials with confidential (at this stage) indications paid for by the Lambert Initiative. Perland has taken much longer to get going than hoped since we signed, and have been doing a raise to fund the trial.

We will soon be in a position that the capsules could be sold as their are, both in the unregistered medicinal cannabis space and the overseas consumer CBD space. It wasn't previously an option, because Catalent would only manufacture for registered pharmaceuticals. We moved manufacturer so that the capsule could be made for all other markets.